Profile data is unavailable for this security.
About the company
Carisma Therapeutics Inc. is a clinical-stage biopharmaceutical company focused on utilizing its proprietary macrophage and monocyte cell engineering platform to develop transformative immunotherapies to treat cancer and other serious diseases. It is developing a pipeline of product candidates, with an initial focus on advancing multiple ex vivo autologous and in vivo CAR-M therapies for the treatment of solid tumors. Its first product candidate, CT-0508, is an ex vivo gene-modified autologous chimeric antigen receptor-monocyte (CAR-Monocyte) cellular therapy intended to treat solid tumors that overexpress human epidermal growth factor receptor 2 (HER2). Its second product candidate, CT-0525, is an ex vivo gene-modified autologous chimeric antigen receptor-macrophage (CAR-Macrophage) cellular therapy intended to treat solid tumors that overexpress HER2. CT-1119 is a mesothelin-targeted CAR-Monocyte that is designed to treat patients with advanced mesothelin-positive solid tumors.
- Revenue in USD (TTM)15.07m
- Net income in USD-81.22m
- Incorporated2008
- Employees107.00
- LocationCarisma Therapeutics Inc245 1st St Ste 1800CAMBRIDGE 02142-1292United StatesUSA
- Phone+1 (617) 444-8550
- Fax+1 (617) 858-0911
- Websitehttps://sesenbio.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Anebulo Pharmaceuticals Inc | 0.00 | -9.35m | 54.46m | 2.00 | -- | 10.92 | -- | -- | -0.3633 | -0.3633 | 0.00 | 0.1922 | 0.00 | -- | -- | 0.00 | -91.51 | -- | -104.28 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -71.89 | -- | -- | -- |
| Rockwell Medical Inc | 86.62m | -8.42m | 54.87m | 237.00 | -- | -- | -- | 0.6335 | -0.3584 | -0.3584 | 3.33 | -- | -- | -- | -- | 365,485.20 | -- | -46.29 | -- | -65.38 | 10.59 | 4.66 | -9.72 | -36.51 | -- | -3.41 | -- | -- | 14.84 | 5.69 | 54.82 | -- | 76.21 | -- |
| Kezar Life Sciences Inc | 7.00m | -101.87m | 56.20m | 58.00 | -- | 0.2995 | -- | 8.03 | -1.40 | -1.40 | 0.0965 | 2.58 | 0.0269 | -- | -- | 120,689.70 | -39.12 | -32.54 | -41.41 | -34.09 | -- | -- | -1,455.29 | -4,308.11 | -- | -- | 0.051 | -- | -- | -- | -49.28 | -- | 10.08 | -- |
| Cidara Therapeutics Inc | 46.38m | -36.47m | 56.29m | 69.00 | -- | -- | -- | 1.21 | -8.07 | -8.07 | 10.26 | -3.90 | 0.6899 | -- | 2.80 | 672,144.90 | -54.24 | -65.23 | -218.59 | -154.37 | 76.93 | -- | -78.63 | -100.61 | 0.6047 | -- | -- | -- | -0.8425 | -- | 31.72 | -- | 23.33 | -- |
| Immix Biopharma Inc | 0.00 | -18.21m | 56.79m | 14.00 | -- | 2.03 | -- | -- | -0.9263 | -0.9263 | 0.00 | 1.06 | 0.00 | -- | -- | 0.00 | -77.50 | -- | -90.46 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -87.44 | -- | -- | -- |
| Calcimedica Inc | 0.00 | -14.94m | 57.83m | 14.00 | -- | 3.35 | -- | -- | -2.64 | -2.64 | 0.00 | 1.61 | 0.00 | -- | -- | 0.00 | -48.34 | -63.99 | -66.59 | -72.71 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 3.51 | -- | -44.35 | -- |
| Carisma Therapeutics Inc | 15.07m | -81.22m | 58.58m | 107.00 | -- | 5.38 | -- | 3.89 | -2.01 | -2.01 | 0.3723 | 0.2623 | 0.1311 | -- | -- | 140,869.20 | -70.64 | -30.87 | -83.17 | -34.47 | -- | -- | -538.81 | -255.66 | -- | -- | 0.1717 | -- | -62.70 | -- | -336.93 | -- | 255.27 | -- |
| Global Pharmatech Inc. | 3.18m | -2.24m | 59.28m | 217.00 | -- | 0.4376 | -- | 18.65 | -0.0964 | -0.0964 | 0.1367 | 0.3428 | 0.2292 | 1.59 | 3.57 | 14,649.77 | -16.44 | -- | -22.55 | -- | 46.21 | -- | -71.75 | -- | 1.62 | -9.87 | 0.2223 | -- | 32.43 | -- | -142.03 | -- | -- | -- |
| VolitionRX Ltd | 797.03k | -34.91m | 59.93m | 110.00 | -- | -- | -- | 75.19 | -0.4603 | -0.4603 | 0.0104 | -0.1901 | 0.0425 | -- | 6.32 | 7,245.73 | -188.25 | -111.92 | -- | -196.20 | -- | -- | -4,425.95 | -10,793.31 | -- | -173.85 | -- | -- | 153.04 | -- | -16.68 | -- | 29.13 | -- |
| Kronos Bio Inc | 7.59m | -116.39m | 60.09m | 61.00 | -- | 0.4387 | -- | 7.92 | -2.00 | -2.00 | 0.1301 | 2.28 | 0.0322 | -- | -- | 122,371.00 | -49.32 | -35.47 | -54.43 | -37.14 | -- | -- | -1,534.11 | -7,975.76 | -- | -- | 0.00 | -- | -- | -- | 15.41 | -- | -8.78 | -- |
| Bakhu Holdings Corp | 0.00 | -1.92m | 60.26m | 2.00 | -- | -- | -- | -- | -0.0064 | -0.0064 | 0.00 | -0.0325 | 0.00 | -- | -- | 0.00 | -281.75 | -4,391.82 | -- | -- | -- | -- | -- | -- | -- | -8.39 | -- | -- | -- | -- | 33.37 | -- | -- | -- |
| Reneo Pharmaceuticals Inc | 0.00 | -70.71m | 61.16m | 8.00 | -- | 0.7528 | -- | -- | -2.17 | -2.17 | 0.00 | 2.43 | 0.00 | -- | -- | 0.00 | -77.06 | -- | -83.08 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -48.95 | -- | -- | -- |
| Protara Therapeutics Inc | 0.00 | -42.47m | 61.56m | 26.00 | -- | 0.5853 | -- | -- | -3.74 | -3.74 | 0.00 | 5.11 | 0.00 | -- | -- | 0.00 | -48.67 | -37.02 | -52.23 | -38.29 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 38.71 | -- | -17.67 | -- |
| RetinalGenix Technologies Inc | 0.00 | -2.09m | 62.25m | 0.00 | -- | -- | -- | -- | -0.1205 | -0.1205 | 0.00 | -0.0797 | 0.00 | -- | -- | -- | -929,284.40 | -9,163.75 | -- | -- | -- | -- | -- | -- | -- | -543.50 | -- | -- | -- | -- | 46.58 | -- | -- | -- |
| Avrobio Inc | 0.00 | 30.31m | 62.85m | 13.00 | 2.03 | 0.7073 | 2.05 | -- | 0.6903 | 0.6903 | 0.00 | 1.98 | 0.00 | -- | -- | 0.00 | 34.57 | -45.22 | 38.47 | -49.14 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 111.48 | -- | -66.27 | -- |
Data as of May 23 2024. Currency figures normalised to Carisma Therapeutics Inc's reporting currency: US Dollar USD
15.11%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| BlackRock Fund Advisorsas of 31 Mar 2024 | 1.60m | 3.84% |
| The Vanguard Group, Inc.as of 31 Mar 2024 | 1.56m | 3.76% |
| University of Pennsylvania (Investment)as of 31 Mar 2024 | 1.25m | 3.01% |
| Geode Capital Management LLCas of 31 Mar 2024 | 528.59k | 1.27% |
| SSgA Funds Management, Inc.as of 31 Mar 2024 | 525.11k | 1.26% |
| Renaissance Technologies LLCas of 31 Mar 2024 | 226.00k | 0.54% |
| Bridgeway Capital Management LLCas of 31 Mar 2024 | 214.88k | 0.52% |
| Northern Trust Investments, Inc.(Investment Management)as of 31 Mar 2024 | 210.70k | 0.51% |
| Teachers Advisors LLCas of 31 Mar 2024 | 86.47k | 0.21% |
| BlackRock Investment Management LLCas of 31 Mar 2024 | 78.39k | 0.19% |
More ▼
Data from 31 Mar 2024 - 31 Mar 2024Source: FactSet Research Systems Inc.
